 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- YB-200 / Ymmunobio
Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1687;
Ethics Approval This animal study has been approved by the Ethics Committee for Animal Experimentation and is registered by the regional board Freiburg, Germany. Mice were handled according to the German animal welfare law and the GV-SOLAS guidelines.